Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879723 | 0.85 | MEN1 (0.48) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL709274 | 0.81 | SMN1; SMN2 (0.50) | HSD11B1MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12377870 | 0.76 | L3MBTL1 (0.62) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL199210 | 0.76 | LPL (0.52) | HSD11B1PSMB5L3MBTL1 | |
| SCHEMBL1559305 | 0.74 | FFAR1 (0.44) | HSD11B1CCR3ALDH1A1 | |
| SCHEMBL7452483 | 0.73 | ACLY (0.53) | HSD11B1MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4604718 | 0.72 | CCR3 (0.45) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL1092164 | 0.72 | SMN1; SMN2 (0.50) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL584175 | 0.72 | SMN1; SMN2 (0.50) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL14387911 | 0.72 | SMN1; SMN2 (0.58) | CYP1A2SMN1; SMN2CCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | HSD11B1 497/4885MEN1 4363/4885CYP1A2 431/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | HSD11B1 497/4885MEN1 4363/4885CYP1A2 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.